Equity-Based Pricing: Enhancing Value in Primary Care through Socioeconomic Considerations
Embedding Equity in Primary Care Incentives
In the English National Health Service (NHS), equity-based pricing offers a promising way to refine value-based mechanisms like the Quality and Outcomes Framework (QOF), a pay-for-performance scheme for primary care. This approach, drawing on distributional cost-effectiveness analysis (DCEA) and contract theory, simulates adjustments to reimbursement prices for influenza vaccination and diabetes education, for example. These changes aim to balance total health gains against their distribution across deprivation levels, measured by the Index of Multiple Deprivation (IMD) quintiles, using the Equally Distributed Equivalent (EDE) index to evaluate trade-offs under different inequality aversion levels (ε), from pure efficiency (ε=0) to strong equity focus.
Uniform Pricing’s Hidden Inequities
Uniform pay-for-performance pricing often overlooks socioeconomic health gradients, with deprived groups (e.g., IMD1) gaining fewer quality-adjusted life-years (QALYs) from interventions like vaccinations due to baseline disparities. For example, a simulated 20% price hike for diabetes influenza vaccination (QOF indicator DM018, from £3.55 to £4.27 per patient), offset by a 6.7% cut in structured education referrals (DM014, from £181.86 to £169.67), projects 1,865 net QALYs across England at a £15,000 per QALY threshold. Yet benefits tilt toward less deprived areas (+440 QALYs in IMD5 vs. +242 in IMD1), increasing inequalities, though EDE stays positive even at high ε (>50), showing efficiency’s edge here.
Resource Shifts Across Conditions
Extending DCEA, another simulation reallocates from chronic obstructive pulmonary disease (COPD) vaccination (COPD007, down 9.8% to £18.14) to diabetes vaccination, delivering +1,771 net QALYs but widening gaps, with EDE improvements under realistic ε values. A deprivation-differentiated scenario—20% price boost for IMD1 diabetes vaccination, funded by a 28.3% IMD5 cut—trims total health by 309 QALYs but boosts equity for lower socioeconomic status groups, yielding EDE gains at ε ≥ 3.3, matching UK estimates. Backed by Clinical Practice Research Datalink (CPRD) Aurum data from 300 practices, this reveals price elasticities (0.15-0.17, deprivation-varying) and IMD-adjusted QALYs (e.g., 0.010-0.019 for COPD vaccination) as key drivers, highlighting equity-based pricing’s role in curbing under-provision in deprived zones.
Quantifying Trade-Offs for HEOR Impact
HEOR advancements in socioeconomic trade-offs for P4P as possible, where QOF’s process focus ignores SES, sustaining inequalities. Equity-based pricing via DCEA could enable differential rates, like higher IMD1 reimbursements for high-burden tasks, preserving efficiency—as in Simulation 3’s EDE at ε=3.5—echoing NHS goals under the Health and Social Care Act 2012 for reducing deprivation in diabetes or COPD outcomes.
In value-based evolution terms (e.g., NICE’s equity appraisals), EDE integration might optimize global budgets, equitably handling costs and aiding therapies for underserved groups. Limitations like multimorbidity data gaps stress better CPRD linkages for SES tracking.
